Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Celldex Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $283.28M, up 30.7% year over year. For fiscal 2025 it was $245.07M, up 49.8% from the year before. Over ten years it grew 9.4% a year on average. The highest annual figure on record is $245.07M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $245.07M | +49.8% |
| FY2024 | Dec 31, 2024 | $163.55M | +38.6% |
| FY2023 | Dec 31, 2023 | $118.01M | +43.5% |
| FY2022 | Dec 31, 2022 | $82.26M | +54.3% |
| FY2021 | Dec 31, 2021 | $53.31M | +25.3% |
| FY2020 | Dec 31, 2020 | $42.53M | -0.3% |
| FY2019 | Dec 31, 2019 | $42.67M | -35.8% |
| FY2018 | Dec 31, 2018 | $66.45M | -30.9% |
| FY2017 | Dec 31, 2017 | $96.17M | -6.4% |
| FY2016 | Dec 31, 2016 | $102.73M | +2.6% |
| FY2015 | Dec 31, 2015 | $100.17M | -4.0% |
| FY2014 | Dec 31, 2014 | $104.38M | +54.9% |
| FY2013 | Dec 31, 2013 | $67.40M | +42.2% |
| FY2012 | Dec 31, 2012 | $47.40M | +46.1% |
| FY2011 | Dec 31, 2011 | $32.44M | +17.3% |
| FY2010 | Dec 31, 2010 | $27.65M | +5.7% |
| FY2009 | Dec 31, 2009 | $26.17M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $67.41M | +7.1% |
| Q2 FY2026 | Jun 30, 2026 | $67.54M | +24.6% |
| Q1 FY2026 | Mar 31, 2026 | $73.00M | +38.7% |
| Q4 FY2025 | Dec 31, 2025 | $75.33M | +60.5% |
| Q3 FY2025 | Sep 30, 2025 | $62.93M | +39.0% |
| Q2 FY2025 | Jun 30, 2025 | $54.20M | +36.6% |
| Q1 FY2025 | Mar 31, 2025 | $52.61M | +66.2% |
| Q4 FY2024 | Dec 31, 2024 | $46.94M | +54.3% |
| Q3 FY2024 | Sep 30, 2024 | $45.26M | +31.1% |
| Q2 FY2024 | Jun 30, 2024 | $39.69M | +51.2% |
| Q1 FY2024 | Mar 31, 2024 | $31.66M | +18.1% |
| Q4 FY2023 | Dec 31, 2023 | $30.43M | +32.9% |
| Q3 FY2023 | Sep 30, 2023 | $34.54M | +60.1% |
| Q2 FY2023 | Jun 30, 2023 | $26.25M | +26.6% |
| Q1 FY2023 | Mar 31, 2023 | $26.80M | +57.1% |
| Q4 FY2022 | Dec 31, 2022 | $22.90M | +56.0% |
| Q3 FY2022 | Sep 30, 2022 | $21.57M | +59.1% |
| Q2 FY2022 | Jun 30, 2022 | $20.73M | +67.8% |
| Q1 FY2022 | Mar 31, 2022 | $17.06M | +34.1% |
| Q4 FY2021 | Dec 31, 2021 | $14.68M | +40.8% |
| Q3 FY2021 | Sep 30, 2021 | $13.56M | +26.6% |
| Q2 FY2021 | Jun 30, 2021 | $12.36M | +27.3% |
| Q1 FY2021 | Mar 31, 2021 | $12.72M | +8.8% |
| Q4 FY2020 | Dec 31, 2020 | $10.43M | +0.8% |
| Q3 FY2020 | Sep 30, 2020 | $10.71M | -3.5% |
| Q2 FY2020 | Jun 30, 2020 | $9.71M | -3.7% |
| Q1 FY2020 | Mar 31, 2020 | $11.70M | +4.9% |
| Q4 FY2019 | Dec 31, 2019 | $10.34M | -7.7% |
| Q3 FY2019 | Sep 30, 2019 | $11.10M | -6.9% |
| Q2 FY2019 | Jun 30, 2019 | $10.08M | -53.0% |
| Q1 FY2019 | Mar 31, 2019 | $11.15M | -49.0% |
| Q4 FY2018 | Dec 31, 2018 | $11.21M | -52.2% |
| Q3 FY2018 | Sep 30, 2018 | $11.92M | -45.6% |
| Q2 FY2018 | Jun 30, 2018 | $21.45M | -14.2% |
| Q1 FY2018 | Mar 31, 2018 | $21.88M | -15.2% |
| Q4 FY2017 | Dec 31, 2017 | $23.46M | -4.5% |
| Q3 FY2017 | Sep 30, 2017 | $21.92M | – |
| Q2 FY2017 | Jun 30, 2017 | $25.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $24.56M | – |
See a number that looks wrong?